Mirabegron: risk of severe hypertension

Mirabegron (Betmiga) is associated with a risk of severe hypertension, cerebrovascular and cardiac events, and is now contraindicated in patients with severe uncontrolled hypertension, the MHRA has advised.

Mirabegron is used in the management of urinary frequency, urgency and incontinence in overactive bladder syndrome.
Mirabegron is used in the management of urinary frequency, urgency and incontinence in overactive bladder syndrome.

Mirabegron is contraindicated in patients with severe uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg) and should be used with caution in patients with stage 2 hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg).

Further information
View Betmiga drug record
MHRA Drug Safety Update
Manufacturer: Astellas Pharma

Cases of severe hypertension, including hypertensive crisis associated with reports of transient ischaemia attack or stroke, have been reported in patients treated with mirabegron. Healthcare professionals should measure blood pressure before and throughout treatment, especially in patients with pre-existing hypertension. 

All suspected adverse reactions associated with mirabegron should be reported in accordance with the MHRA Yellow Card Scheme.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New guidance for minimising psychological impact of COVID-19 pandemic in primary care patients
Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

MIMS launches Respiratory and Allergy Learning webinars

MIMS launches Respiratory and Allergy Learning webinars

Join us for the 2020 Respiratory and Allergy Learning...